Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

OUS Approvals Analysis: Summer Brings Slowdown In CE Marks

Executive Summary

Medtech Insight’s new Approvals Tracker recorded 18 approvals outside the US, including five in vitro diagnostic approvals and five cardiovascular device approvals.

You may also be interested in...



US Approvals Analysis: July A Good Month For PMAs; 510(k)s Down In 2016

A look at Medtech Insight's Approval Tracker data shows that last month was a relatively active one for US FDA approvals of novel devices via the PMA, panel-track supplement and de novo routes. But 510(k) clearance totals are down so far in 2016 compared to recent years.

US Approvals Analysis: July A Good Month For PMAs; 510(k)s Down In 2016

A look at Medtech Insight's Approval Tracker data shows that last month was a relatively active one for US FDA approvals of novel devices via the PMA, panel-track supplement and de novo routes. But 510(k) clearance totals are down so far in 2016 compared to recent years.

Pixium's IRIS II CE Mark Stokes Retinal Implant Rivalry

Competition in the retinal implant market heats up as Pixium CE marks its second-generation bionic vision system, designed to offer key advantages including higher resolution and explantability.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT103683

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel